3D Cell Cultures Market to Cross US$ 3.1 Billion on by 2033 Driven by Increased Biological Relevance and Rising Incidence of Chronic Diseases | Persistence Market Research
January 18, 2024 04:30 ET
|
Persistence Market Research
New York, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview: In 2022, the 3D cell culture market reached a global revenue of US$1.2 billion, and projections indicate a Compound Annual...
FRED’S TEAM SETS HISTORIC $8 MILLION FUNDRAISING RECORD FOR CANCER RESEARCH
January 17, 2024 09:00 ET
|
Memorial Sloan Kettering Cancer Center
New York, NY, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Fred’s Team, the official running program of Memorial Sloan Kettering Cancer Center (MSK), set a new single-season fundraising record in 2023 by...
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
December 08, 2023 09:15 ET
|
Novartis Pharma AG
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
ELISpot and FluoroSpot Assay Market is Expected to Reach $421 million | MarketsandMarkets.
December 04, 2023 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Dec. 04, 2023 (GLOBE NEWSWIRE) -- ELISpot and FluoroSpot Assay market in terms of revenue was estimated to be worth $292 million in 2023 and is poised to reach $421 million by 2028, growing...
Cell Culture Consumables Market revenue to reach USD 400 Billion by 2036, says Research Nester
November 21, 2023 07:30 ET
|
Research Nester
New York, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The global cell culture consumables market size is projected to grow at a CAGR of over ~23% from 2024 to 2036. The market is expected to garner a revenue...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2023 06:00 ET
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023 16:10 ET
|
Prelude Therapeutics, Inc.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023 16:05 ET
|
Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
October 30, 2023 06:00 ET
|
Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Global Preclinical Imaging Market Set to Reach $5.95 Billion by 2030, Driven by Research and Development Investments
October 18, 2023 09:53 ET
|
Research and Markets
Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Market Size, Share & Trends Analysis Report By Product (CT Imaging, Services, Ultrasound Imaging), By Application (Research and...